Elite Pharmaceuticals Inc (ELTP)

[Couch]

Puny must be how many of Elite's competitors have more abuse deterrent opioids compared to even the current one's in Elite's pipeline. The writing is on the wall and here it is. LMMFAO

Next step, what are we thinking about once we file. We believe the FDA will brand us, expedite the review and we’ll give us results probably by – or approval by September of 2015. That will be the date where we’d be launching and about a year from now, August, September of 2015. To do so we have to decide what we’re doing our product. I have made the decision we will be manufacturing ELI-200 ourselves.

I have had several companies that approached me and asked if contract manufacture for us, they have much bigger facilities and I’ve decided the product is staying with us. The marketing of the product, we have several options. We either contract the sales and marketing force, and Chris and I have been in contact with such entities and that proposals and numbers and what have you.

And the second is to have a well-established pharmaceutical company that has the capabilities and sales and marketing force of 150 to 200 people that can sell our product in addition to this at some kind of a profit sharing or commission. I have not made the decision on that part and that will have to be made by December once we file, okay.

This is the status of the ELI-200. It is the most exciting product we have right now. We are filing an application, which have never happened in the history of this company. We’re launching an awesome product. I mean this is exceptionally exciting.

We have several other products in development that we’ve updated to you on. We’ll start with the clinical trials for ELI-201, same thing with ELI-202. Again, the results and data will be available in October probably. We filed INDs for all of them. We’re in communication with FDA on what is required and all of that part is exciting, but the filing will take place in December of this year for ELI-200 and that really is our flagship.